利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.047 秒)

    Antibodies to treat cancer
    1.
    发明授权
    Antibodies to treat cancer 有权
    治疗癌症的抗体

    公开(公告)号：US07781569B2

    公开(公告)日：2010-08-24

    申请号：US11414532

    申请日：2006-04-28

    申请人： Gary Fanger ,  Neil Fanger ,  David John King ,  Marc W. Retter ,  Kenneth L. Rock

    发明人： Gary Fanger ,  Neil Fanger ,  David John King ,  Marc W. Retter ,  Kenneth L. Rock

    IPC分类号： C07K16/00

    CPC分类号： C07K16/30 ,  A61K2039/505 ,  C07K2317/73 ,  C07K2317/732

    摘要： Compositions and methods for the treatment of cancer, particularly melanoma, myeloma, small cell lung cancer, thymic lymphoma, T-cell lymphoma, B-cell lymphoma, osteosarcoma, and acute T-cell leukemia, are disclosed. Illustrative compositions include one or more anti-ganglioside antibodies and polynucleotides that encode such anti-ganglioside antibodies. These antibodies may be for example, hamster antibodies, chimeric human/hamster antibodies, or humanized antibodies. The disclosed compositions are useful, for example, in the treatment of cancer and can be used to induce apoptosis in a cancer cell.

    摘要翻译： 公开了用于治疗癌症，特别是黑素瘤，骨髓瘤，小细胞肺癌，胸腺淋巴瘤，T细胞淋巴瘤，B细胞淋巴瘤，骨肉瘤和急性T细胞白血病的组合物和方法。 说明性组合物包括一种或多种编码这种抗神经节苷脂抗体的抗神经节苷脂抗体和多核苷酸。 这些抗体可以是例如仓鼠抗体，嵌合人/仓鼠抗体或人源化抗体。 所公开的组合物可用于例如治疗癌症，并可用于诱导癌细胞中的细胞凋亡。

    Antibodies to treat cancer
    2.
    发明授权
    Antibodies to treat cancer 有权
    治疗癌症的抗体

    公开(公告)号：US07935338B2

    公开(公告)日：2011-05-03

    申请号：US10317747

    申请日：2002-12-11

    申请人： Gary R. Fanger ,  Neil Fanger ,  David King ,  Marc W. Retter ,  Kenneth L. Rock

    发明人： Gary R. Fanger ,  Neil Fanger ,  David King ,  Marc W. Retter ,  Kenneth L. Rock

    IPC分类号： A61K39/395

    CPC分类号： C07K16/30 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/732

    摘要： Compositions and methods for the treatment of cancer, particularly melanoma, myeloma, small cell lung cancer, thymic lymphoma, T-cell lymphoma, B-cell lymphoma, osteosarcoma, and acute T-cell leukemia, are disclosed. Illustrative compositions include one or more anti-ganglioside antibodies and polynucleotides that encode such anti-ganglioside antibodies. These antibodies may be for example, hamster antibodies, chimeric human/hamster antibodies, or humanized antibodies. The disclosed compositions are useful, for example, in the treatment of cancer and can be used to induce apoptosis in a cancer cell.

    摘要翻译： 公开了用于治疗癌症，特别是黑素瘤，骨髓瘤，小细胞肺癌，胸腺淋巴瘤，T细胞淋巴瘤，B细胞淋巴瘤，骨肉瘤和急性T细胞白血病的组合物和方法。 说明性组合物包括一种或多种编码这种抗神经节苷脂抗体的抗神经节苷脂抗体和多核苷酸。 这些抗体可以是例如仓鼠抗体，嵌合人/仓鼠抗体或人源化抗体。 所公开的组合物可用于例如治疗癌症，并可用于诱导癌细胞中的细胞凋亡。

    Compositions and methods for inducing cytotoxic T lymphocyte responses by immunization with protein antigens
    4.
    发明授权
    Compositions and methods for inducing cytotoxic T lymphocyte responses by immunization with protein antigens 失效
    用蛋白质抗原免疫诱导细胞毒性T淋巴细胞反应的组合物和方法

    公开(公告)号：US06328972B1

    公开(公告)日：2001-12-11

    申请号：US08425679

    申请日：1995-04-18

    申请人： Kenneth L. Rock

    发明人： Kenneth L. Rock

    IPC分类号： A61K39385

    CPC分类号： A61K9/167 ,  A61K39/00 ,  A61K2039/60 ,  Y02A50/466 ,  Y10S977/802 ,  Y10S977/803 ,  Y10S977/915 ,  Y10S977/917 ,  Y10S977/918 ,  Y10S977/92

    摘要： The invention provides compositions and methods for inducing MHC class I-restricted cytotoxic T lymphocyte responses in a mammalian host by immunization with non-replicating protein antigens. The compositions of the invention comprise a two-component complex including a particle component, which is not a prokaryotic or eukaryotic cell, or a micellar, multimicellar, or liposome vesicle composed of detergents and/or lipids, ranging in size from about 10 nm to about 50 &mgr;m, and a non-replicating protein antigen. The non-replicating protein antigen is attached to the particle component through a covalent or non-covalent association to form particulate protein antigen complexes and the complexes are administered to a mammalian host in conjunction with a pharmaceutically acceptable excipient, in a CTL-stimulatory amount. The invention also provides non-replicating vaccines and methods of vaccinating a mammalian host for CTL immunity.

    摘要翻译： 本发明提供了通过用非复制蛋白抗原免疫在哺乳动物宿主中诱导MHC I类限制性细胞毒性T淋巴细胞应答的组合物和方法。 本发明的组合物包含双组分复合物，其包括不是原核或真核细胞的颗粒组分，或由洗涤剂和/或脂质组成的胶束，多片或脂质体囊泡，其尺寸范围为约10nm至 约50微克，以及非复制蛋白质抗原。 非复制蛋白质抗原通过共价或非共价缔合连接到颗粒组分上以形成颗粒蛋白抗原复合物，并且将复合物以CTL刺激量与药学上可接受的赋形剂联合施用于哺乳动物宿主。 本发明还提供了非复制疫苗和用于CTL免疫接种哺乳动物宿主的方法。

    Endogenous adjuvant molecules and uses thereof
    5.
    发明授权
    Endogenous adjuvant molecules and uses thereof 有权
    内源性佐剂分子及其用途

    公开(公告)号：US08597664B2

    公开(公告)日：2013-12-03

    申请号：US12879471

    申请日：2010-09-10

    申请人： Kenneth L. Rock ,  Yan Shi

    发明人： Kenneth L. Rock ,  Yan Shi

    IPC分类号： A61K39/00

    CPC分类号： A61K39/39 ,  A61K2039/55505 ,  A61K2039/55511

    摘要： Methods of modulating the immune response using pharmaceutical compositions containing crystalline adjuvants are described. In various embodiments the crystalline adjuvants are selected from the group consisting of monosodium urate (MSU), xanthine, basic calcium phosphate (BCP), calcium pyrophosphate dihydrate (CPPD), hydroxyapatite, calcium oxalate, cholesterol, lipid liquid, other crystalline lipids, lithium heparin, talc, and starch.

    摘要翻译： 描述了使用含有结晶佐剂的药物组合物调节免疫应答的方法。 在各种实施方案中，结晶佐剂选自由尿酸单钠（MSU），黄嘌呤，碱式磷酸钙（BCP），焦磷酸钙二水合物（CPPD），羟基磷灰石，草酸钙，胆固醇，脂质液体，其它结晶脂质，锂 肝素，滑石粉和淀粉。

    Stimulation of cell-mediated immune responses by targeted particulate genetic immunization
    6.
    发明授权
    Stimulation of cell-mediated immune responses by targeted particulate genetic immunization 失效
    通过靶向颗粒遗传免疫刺激细胞介导的免疫应答

    公开(公告)号：US07176186B1

    公开(公告)日：2007-02-13

    申请号：US08931219

    申请日：1997-09-16

    申请人： Louis D. Falo, Jr. ,  Kenneth L. Rock

    发明人： Louis D. Falo, Jr. ,  Kenneth L. Rock

    IPC分类号： A61K48/00 ,  A61K35/00 ,  C12N15/09 ,  C12N15/85

    CPC分类号： C12N15/895 ,  A61K31/711 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/292 ,  A61K48/00 ,  A61K2039/53 ,  A61K2039/54

    摘要： The present invention relates to various methods of genetic immunization for the purpose of providing antigen-specific immunity in a mammalian host, including a human host. The invention is based on the ability to direct particulate polynucleotides which express an antigenic protein or protein fragment to the cytoplasm of host target cells, such as antigen presenting cells. A directed delivery of such particulate polynucleotides to the cytoplasm of antigen presenting cells will stimulate antigen-specific CTL production, thus promoting destruction of affected cells such as neoplastic cells and virally infected cells.

    摘要翻译： 本发明涉及在哺乳动物宿主（包括人宿主）中提供抗原特异性免疫的基因免疫的各种方法。 本发明基于将表达抗原蛋白或蛋白质片段的颗粒多核苷酸引导至宿主靶细胞例如抗原呈递细胞的细胞质的能力。 将这种颗粒状多核苷酸定向递送到抗原呈递细胞的细胞质将刺激抗原特异性CTL产生，从而促进受影响细胞如肿瘤细胞和病毒感染细胞的破坏。

    Induction of CTLs specific for natural antigens by cross priming immunization
    7.
    发明授权
    Induction of CTLs specific for natural antigens by cross priming immunization 失效
    通过交叉引发免疫诱导天然抗原特异性CTL

    公开(公告)号：US5951975A

    公开(公告)日：1999-09-14

    申请号：US675332

    申请日：1996-06-28

    申请人： Louis D. Falo, Jr. ,  Kenneth L. Rock

    发明人： Louis D. Falo, Jr. ,  Kenneth L. Rock

    IPC分类号： A61K48/00 ,  A61K35/12 ,  A61K39/00 ,  A61K39/12 ,  A61P35/00 ,  A61P43/00 ,  A01N63/00 ,  A61K39/29

    CPC分类号： A61K39/0011

    摘要： The present invention relates to prophylactic and therapeutic methods of anti-tumor immunization. These methods are based on cross-priming a mammalian host to natural MHC class I restricted tumor antigens with an artificial tumor antigen. A primary tumor is resected from the patient and a population of tumor cells are cultured in vitro. These cultured tumor cells are loaded with an artificial target antigen. The loaded tumor cells are inactivated and introduced into the patient either simultaneous or subsequent to a direct immunization of the patient with the same or substantially the same artificial target antigen. This method of coupled host immunization promotes a tumor specific cytotoxic T lymphocyte (CTL) immune response against multiple, undefined natural tumor antigens expressed on the unmodified tumor cell surface.

    摘要翻译： 本发明涉及抗肿瘤免疫的预防和治疗方法。 这些方法是基于将哺乳动物宿主与天然MHC I类限制性肿瘤抗原与人造肿瘤抗原交叉引物。 从患者切除原发性肿瘤，并在体外培养一批肿瘤细胞。 这些培养的​​肿瘤细胞装载有人工靶抗原。 加载的肿瘤细胞在与相同或基本相同的人造靶抗原直接免疫患者的同时或之后被灭活并引入患者体内。 这种偶联宿主免疫的方法促进针对在未修饰的肿瘤细胞表面上表达的多种未定义的天然肿瘤抗原的肿瘤特异性细胞毒性T淋巴细胞（CTL）免疫应答。

    Endogenous adjuvant molecules and uses thereof
    9.
    发明授权
    Endogenous adjuvant molecules and uses thereof 有权
    内源性佐剂分子及其用途

    公开(公告)号：US07807187B2

    公开(公告)日：2010-10-05

    申请号：US10846381

    申请日：2004-05-13

    申请人： Kenneth L. Rock ,  Yan Shi

    发明人： Kenneth L. Rock ,  Yan Shi

    IPC分类号： A61K39/00

    CPC分类号： A61K39/39 ,  A61K2039/55505 ,  A61K2039/55511

    摘要： Methods of modulating the immune response using pharmaceutical compositions containing crystalline adjuvants are described. In various embodiments the crystalline adjuvants are selected from the group consisting of monosodium urate (MSU), xanthine, basic calcium phosphate (BCP), calcium pyrophosphate dihydrate (CPPD), hydroxyapatite, calcium oxalate, cholesterol, lipid liquid, other crystalline lipids, lithium heparin, talc, and starch.

    摘要翻译： 描述了使用含有结晶佐剂的药物组合物调节免疫应答的方法。 在各种实施方案中，结晶佐剂选自由尿酸单钠（MSU），黄嘌呤，碱式磷酸钙（BCP），焦磷酸钙二水合物（CPPD），羟基磷灰石，草酸钙，胆固醇，脂质液体，其他结晶脂质，锂 肝素，滑石粉和淀粉。

    Method for enhancing the association of exogenous peptides with class I MHC molecules on the surface of antigen presenting cells with .beta.-microglobulin
    10.
    发明授权
    Method for enhancing the association of exogenous peptides with class I MHC molecules on the surface of antigen presenting cells with .beta.-microglobulin 失效
    增强抗原呈递细胞表面的外源肽与I型MHC分子在β-微球蛋白表面的结合的方法

    公开(公告)号：US5733550A

    公开(公告)日：1998-03-31

    申请号：US461213

    申请日：1995-06-05

    申请人： Kenneth L. Rock

    发明人： Kenneth L. Rock

    IPC分类号： A61K38/17 ,  A61K39/385 ,  A61K39/39 ,  A61K39/00 ,  A01N63/00 ,  C07K1/00 ,  C07K14/00

    CPC分类号： A61K39/385 ,  A61K38/1774 ,  A61K39/39 ,  A61K2039/5158 ,  A61K2039/57 ,  A61K2039/605

    摘要： The present invention provides a method for enhancing the association of exogenous peptides with class I MHC molecules on the surface of antigen presenting cells to thereby sensitize the target cells for class I MHC-restricted cytotoxic T cell response. The method involves obtaining the peptides of interest and presenting the peptides to the appropriate antigen presenting cells in the presence of an elevated level of free .beta..sub.2 -microglobulin. The method of the present invention can also be used to prime naive populations of T lymphocytes for antigen-specific class I MHC-restricted cytotoxic T cell response with exogenous peptide and is useful in both in vitro and in vivo applications. A new use for purified .beta..sub.2 -microglobulin as an adjuvant for synthetic peptide vaccines is also provided.

    摘要翻译： 本发明提供了增强外源肽与抗原呈递细胞表面上的I类MHC分子的缔合的方法，从而使目标细胞对I MHC限制性细胞毒性T细胞应答敏感。 该方法包括获得感兴趣的肽并且在存在升高水平的游离β2-微球蛋白的情况下将肽​​呈递给合适的抗原呈递细胞。 本发明的方法还可以用于使用外源性肽来产生用于抗原特异性I类MHC限制性细胞毒性T细胞应答的T淋巴细胞的初始群体，并且在体外和体内应用中都是有用的。 还提供了用于纯化的β2-微球蛋白作为合成肽疫苗佐剂的新用途。